Attribution of NF-κB Activity to CHUK/IKKα-Involved Carcinogenesis

Xin Li and Yinling Hu *

Laboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA; xin.li3@nih.gov

* Correspondence: huy2@mail.nih.gov

Simple Summary: CHUK/IKKα has emerged as a novel tumor suppressor in several organs of humans and mice. In general, activation of NF-κB promotes inflammation and tumorigenesis. IKKα reduction stimulates inflammatory responses including NF-κB's targets and NF-κB-independent pathways for tumor promotion. Specific phenomena from genetically-modified mice and human TCGA database show the crosstalk between IKKα and NF-κB although their nature paths for normal organ development and the disease and cancer pathogenesis remains largely under investigation. In this review, we focus on the interplay between IKKα and NF-κB signaling during carcinogenesis. A better understanding of their relationship will provide insight into therapeutic targets of cancer.

Abstract: Studies analyzing human cancer genome sequences and genetically modified mouse models have extensively expanded our understanding of human tumorigenesis, even challenging or reversing the dogma of certain genes as originally characterized by in vitro studies. Inhibitor-κB kinase α (IKKa), which is encoded by the conserved helix-loop-helix ubiquitous kinase (CHUK) gene, is first identified as a serine/threonine protein kinase in the inhibitor-κB kinase complex (IKK), which is composed of IKKα, IKKβ, and IKKγ (NEMO). IKK phosphorylates serine residues 32 and 36 of IκBα, a nuclear factor-κB (NF-κB) inhibitor, to induce IκBα protein degradation, resulting in the nuclear translocation of NF-κB dimers that function as transcriptional factors to regulate immunity, infection, lymphoid organ/cell development, cell death/growth, and tumorigenesis. NF-κB and IKK are broadly and differentially expressed in the cells of our body. For a long time, the idea that the IKK complex acts as a direct upstream activator of NF-κB in carcinogenesis has been predominately accepted in the field. Surprisingly, IKKα has emerged as a novel suppressor for skin, lung, esophageal, and nasopharyngeal squamous cell carcinoma, as well as lung and pancreatic adenocarcinoma (ADC). Thus, Ikkα loss is a tumor driver in mice. On the other hand, lacking the RANKL/RANK/IKKα pathway impairs mammary gland development and attenuates oncogene- and chemical carcinogen-induced breast and prostate tumorigenesis and metastasis. In general, NF-κB activation leads one of the major inflammatory pathways and stimulates tumorigenesis. Since IKKα and NF-κB play significant roles in human health, revealing the interplay between them greatly benefits the diagnosis, treatment, and prevention of human cancer. In this review, we discuss the intriguing attribution of NF-κB to CHUK/IKKα-involved carcinogenesis.

Keywords: IKKα; NF-κB; Carcinogenesis

1. Introduction

Five NF-κB transcriptional factors, including RelA (p65), RelB, c-Rel, NF-κB1 (p50), and NF-κB2 (p52), are differentially expressed in a wide range of cell types and execute their physiological functions through the compositions of their homodimers or heterodimers (Figure 1) [1]. Studies using genetically modified mouse models show that the biological roles of these transcription factors partially overlap [2]. These NF-κB components are classified into the canonical and non-canonical NF-κB pathways, as initiated by their
upstream regulators [3,4]. In the canonical signaling (Figure 1), the NF-κB inhibitor IkBα interacts with NF-κB p65/p50 dimers that mask the nuclear localization signal of NF-κB, thereby blocking NF-κB’s nuclear translocation from cytosol to nucleus and inactivating NF-κB. In the non-canonical signaling, an NF-κB-inducing kinase (NIK) activates IKKα, which then phosphorylates and then cleaves the p100 to generate p52, resulting in RelB/p52 dimer nuclear translocation [4,5]. The activated NF-κB functions as a transcriptional factor by binding to the DNA consensus sequences on the regulatory elements of the target genes.

IKKα and IKKβ, which are highly conserved protein kinases containing a protein kinase domain, a leucine zipper motif, and a helix-loop-helix motif, are catalytical subunits [6–10]. IKKγ is a regulatory subunit in the IKK complex. There is an IKKγ binding motif at the end of the C-terminus of IKKα and IKKβ. Following activation of the receptors, the activated IKK stimulates canonical and non-canonical NF-κB activation and transduces signals from external cells to the cellular nucleus. These IKK subunits are not functionally redundant because Ikkα−/−, Ikkβ−/−, or Ikkγ−/− mice display severe phenotypes (Table 1), although Ikkβ−/−, Ikkγ−/−, and p65−/− mice show a similar phenotype of embryonic lethality from hemorrhage mediated by liver cell death and are rescued by Tnfr1 deletion, which blocks cell death [11–17]. Ikkα−/− mice die within 15 minutes after birth due to water loss from severely impaired skin, and Tnfr1 deletion does not rescue them [18]. Thus, IKKα plays a distinct physiological function from IKKβ and IKKγ during embryonic development.

Human IKBKB mutations

Infants and children with IKBKB mutations show severe infection Reduced NF-κB activity Detected mutations but not known for lung cancer survival [30–33]

Figure 1. A model of canonical and non-canonical NF-κB pathways. (aa: amino acid; two IKKα molecules form a homodimer in the non-canonical NF-κB pathway).
Table 1. Comparison of physiological activities and IKK/NF-κB activities in genetically modified mice and humans.

| Mice                  | Developmental Phenotypes                                      | Tnfr1 KO/NF-κB                                                                 | Tumorigenesis                                                                 | References                          |
|-----------------------|--------------------------------------------------------------|-------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-------------------------------------|
| Ikkα−/−               | Die soon after birth, marked epidermal hyperplasia           | Tnfr1 KO does not rescue mutants; slightly reduced or increased NF-κB activity | Ikκα−/− mice develop carcinogen-induced skin carcinogenesis                   | [11,18,19]                         |
| Ikkβ−/−               | Embryonic lethality, liver cell apoptosis, hemorrhage        | Tnfr1 KO rescues mutants, blocks NF-κB activity                               | Not tested                                                                    | [15,16]                            |
| Ikkγ−/−               | Embryonic lethality, liver cell apoptosis, hemorrhage        | Tnfr1 KO rescues mutants, blocks NF-κB activity                               | Not tested                                                                    | [13,14]                            |
| p65(Rela)−/−          | Embryonic lethality, liver cell apoptosis, hemorrhage        | Tnfr1 KO rescues mutants, blocks NF-κB activity                               | Not tested                                                                    | [12,17]                            |
| Tg-K5.mIkBx           | Normal embryonic development; skin phenotypes with cell apoptosis and inflammation | Tnfr1 KO rescues mutants                                                     | Spontaneous skin tumors                                                      | [20,21]                            |
| Tg-K5.IKKα            | Normal mice and normal skin from one day to more than one year | Not tested for Tnfr1 KO; no increase in skin NF-κB                            | Inhibit UVB-induced skin carcinogenesis; rescue lung squamous cell carcinomas and autoimmunity | [22–24]                           |
| Tg-IKKβ               | Normal embryonic development                                 | Not tested for Tnfr1 KO; increased NF-κB activity                             | Epidermal hyperplasia and spontaneous oral tumors                            | [25,26]                            |
| Tg-EDL2.IKKβ          | Normal embryonic development                                 | Not tested for Tnfr1 KO; increased NF-κB activity                             | Esophageal hyperplasia                                                       | [27]                               |
| Ikβ−/−                | Die within 6 weeks after birth with severe skin inflammation | Not tested for Tnfr1 KO; increased NF-κB activity                             | Not tested                                                                    | [28]                               |
| Human CHUK mutations  | Mutations at amino acid 422 to generate a stop code; embryonic lethality at 12–14 weeks | Appearance like Ikκα−/− mice; defects in the face, limbs, kidneys, heart, lungs, bone | Gene mutations and deletions associated with reduced survival of lung adenocarcinoma patients | [29]                               |
| Human IKBKB mutations | Infants and children with IKBKB mutations show severe infection | Reduced NF-κB activity                                                       | Detected mutations but not known for lung cancer survival                    | [30–33]                           |

Following ligand stimulation, activated receptors on cell surfaces transduce signals from external cells to the cellular cytosol and nucleus, leading to the activation or suppression of specific pathways and events at various levels in the cells. TNFR family members, such as TNFR1/TNF, LTβR/LTβ, BAFFR/BAFF, CD40/CD40L, and RANK/RANKL, which are differentially expressed in a broad variety of specific cells, execute distinct biological activities and regulate tumorigenesis. In general, increased NF-κB activity promotes tumorigenesis. For example, defective RANKL/RANK/IKKα signaling impairs mammary gland development and damps oncogene-mediated breast carcinogenesis [34]. IKKα loss, meanwhile, promotes the development of cutaneous, lung, and esophageal squamous cell carcinomas (SCCs) and lung and pancreatic ADCs [19,22,23,35–40], which are associated with increased NF-κB related targets and inflammation. However, the way in which IKKα crosstalks with the NF-κB pathway remains to be fully elucidated. Here, we discuss the connections between IKKα and NF-κB activity in skin, lung, and esophageal SCCs; lung and pancreatic ADCs; and breast and prostate cancer.

2. IKKα, NF-κB, and Carcinogenesis

2.1. Squamous Cell Carcinoma

The surfaces of our bodies, some internal organs, and the interface of the tracts, which connect or are located inside organs, are covered by the epithelium, which is composed of a similar type of squamous or pseudo-squamous epithelial cells and protect these organs and our body. The basal cells of the squamous epithelium express keratin 5 (K5), K14, and p63 and are able to proliferate and differentiate in response to various stimuli, including growth factors, cytokines, chemokines, inflammatory irritants, and chemical carcinogens. These basal cells are also able to give rise to benign papilloma and malignant SCC. Deletions and
reduction of CHUK, which encodes IKKa, reportedly promote SCC development in the skin, lungs, oral cavity, esophagus, and nasopharynx of humans [19,22,23,35–40].

2.1.1. Skin Diseases and Cutaneous SCC

**IKKa activity in mouse embryonic development.** The skin, which is made up of the epidermis and dermis, is the largest organ. The epidermis consists of undifferentiated to terminally differentiated keratinocytes (a type of squamous epithelial cells) that form the cornified layer and protects our bodies. \( Ikkα^{−/−} \) newborns have a strikingly thick epidermis that lacks the terminally differentiated keratinocytes and has significantly increased numbers of K5/K14- and Ki67-positive cells. As a result, bodily fluids flow out of \( Ikkα^{−/−} \) skin, which causes the mutant mice to die [11]. Reintroducing IKKa in vivo and in vitro rescues the undifferentiation defect in \( Ikkα^{−/−} \) mouse keratinocytes and the mutant mice [41]. Meanwhile, the fetal liver is a major target for IKK\( β \), IKK\( γ \), and p65 during embryonic development [14,15,17]; whereas LPS injection induces a comparable level of the IKK kinase activity in the liver of \( Ikkα^{−/−} \) and wild-type (WT) newborn pups [11]. The 32 and 36 serine residues of IkB\( \alpha \) are used as a kinase substrate, analyzed by an immunoprecipitated kinase assay with an anti-IKK\( α \) antibody. \( Ikkα^{−/−} \) embryonic fibroblasts remain at a similar or slightly decreased NF-\( κB \) and IKK activity level in response to TNFa or IL-1\( β \) stimulation compared to WT cells, as detected with an anti-IKK\( β \) antibody immunoprecipitated kinase assay [11]. Of interest, an anti-IKK\( α \) antibody immunoprecipitated kinase assay showed slightly higher kinase activity in \( Ikkα^{−/−} \) fibroblasts than in WT cells in response to IL-1\( β \) but not TNFa stimulation [41]. In addition, the IKK kinase and NF-\( κB \) activities increase in response to these stimuli in primary cultured \( Ikkα^{−/−} \) keratinocytes compared to WT. Collectively, IKK\( α \) deletion is not able to fully block the IKK kinase and NF-\( κB \) activities compared to IKK\( β \) or IKK\( δ \) deletion, or else IKK\( α \) deletion elevates IKK/NF-\( κB \) activity, depending on cell type.

*The importance of CHUK/IKK\( α \) in human embryonic development.* A CHUK nonsense mutation that creates a stop code at amino acid 422 to generate a truncated and unstable protein, which in turn causes IKK\( α \) loss, is identified in an autosomal recessive lethal syndrome [29]. The appearance of the mutant human fetuses at 12 to 13 weeks old, which is characterized by multiple defects in the face, limbs, kidneys, heart, skull bones, and lungs, is similar to that of the \( Ikkα^{−/−} \) newborn pups (Table 1). Thus, CHUK/IKK\( α \) is essential for human embryonic development. On the other hand, humans with a IKBK\( β \) gene deletion undergo the normal embryonic development but suffer severe bacterial, viral, and fungal infections after birth [30–33]. Thus, IKK\( α \) is required for human and mouse embryonic development independently of TNFR1, while IKK\( β \) and IKK\( γ \) are essential for protecting liver cells of mouse embryos from apoptosis through a TNFR1-led NF-\( κB \) pathway (Table 1).

**IKK\( α \) Transgene versus \( Ikkα \) gene deletion in skin inflammation and tumorigenesis.** Of note, Tg-K5.mIk\( β \) transgenic mice, in which there is a super suppressor mIk\( β \) with mutations at amino acids 32 and 36 from serine to alanine, develop spontaneous skin SCCs associated with increased inflammation (Table 1) [20]. Ablation of the Tnfr1 gene abolishes skin inflammation and SCC in Tg-K5. mIk\( β \);Tnfr1\( −/− \) mice [21]. Thus, it has been suggested that decreased NF-\( κB \) activity promotes skin tumorigenesis. However, Tg-K5.IKK\( β \) mice show epidermal hyperplasia and oral tumors (Table 1) [25,26], and Tg-EDL2.IKK\( β \) mice that overexpress IKK\( β \) in the esophageal epithelial cells also develop hyperplasia in the esophagus [27]. On the other hand, Tg-K5.IKK\( α \) mice develop normal skin and esophagus at one day and one year of age [24]. Thus, the role of IKK and NF-\( κB \) in skin homeostasis and tumorigenesis is intriguing.

\( Ikkα^{+/−} \) mice, which look normal, develop twice as many papillomas and 10 times as many malignant SCCs than \( Ikkα^{+/+} \) mice in the chemical carcinogen-induced carcinogenesis setting [19] (Table 1). These \( Ikkα^{+/−} \) SCCs lost the WT \( Ikkα \) allele, and IKK kinase activity is increased compared to \( Ikkα^{+/+} \) carcinomas, which is correlated with increased ERK activity, poorly differentiated cell features, and WT \( Ikkα \) allele loss [19], indicating that
IKKα loss promotes the malignant conversion from papillomas to carcinomas. Moreover, the expression of IL-1α, TNFα, TGFα, EGF, amphiregulin, HB-EGF, FGF2, FGF3, and VEGFA is higher in *Ikka*+/− skin than in *Ikka*+/+ skin, treated with a chemical skin-tumor-promoter (inflammatory irritant). Although the chemical carcinogen stimulates IKKα expression in the normal skin and early benign tumors [19,42], the heterozygous *Ikka* gene (*Ikka*+/−) expresses a half dose of induced IKKα in response to stimuli compared to WT (*Ikka*+/+), which attenuates IKKα anti-tumor activity. Thus, IKKα is a tumor suppressor with a haplo-insufficient feature.

To demonstrate whether IKKα loss induces spontaneous skin tumors, we ablated *Ikka* with K5.Cre and found that *Ikka*Δ/Δ.K5.Cre mice die within three weeks after birth [37] (Table 2). Furthermore, the inducible ablation of *Ikka* in the basal keratinocytes or stem cells of adult *Ikka*Δ/Δ mice by inducible K5.CreER or K15.CreRIP with tamoxifen or RU486 results in spontaneous skin papillomas and SCCs [37]. Thus, IKKα deletion is a tumor driver. The tumor microenvironment modulates tumorigenesis. We have shown that inflammatory cytokines downregulate IKKα levels [23]. IKKα inactivation and increased macrophage numbers upregulate the expression of cytokines and chemokines, which are targets of NF-κB [43–46], and result in spontaneous lung SCCs, although the underlying mechanism requires further investigation.

Table 2. Comparison of physiological activities and tumorigenesis in mice lacking IKK/NF-κB in specific tissues.

| Mice               | Neonatal Phenotypes                                                                 | Tnfr1 KO/NF-κB                                                                 | Tumorigenesis                                                                 | References |
|--------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------|
| *Ikka*Δ/Δ.K5.Cre   | Die within 3 weeks; neonatal epidermal hyperplasia and severe inflammation           | Tnfr1 KO does not rescue mutants; increased TNF and NF-κB                      | NA                                                                            | [37]       |
| *Ikka*Δ/Δ.K14.Cre  | Die within 3 weeks; neonatal epidermal hyperplasia and severe inflammation           | Not rescued                                                                    | NA                                                                            | [37]       |
| *Ikkr*Δ/Δ.K14.Cre  | Die within 3 weeks; neonatal epidermal hyperplasia and severe inflammation           | Tnfr1 KO rescues mutants and skin lesions                                      | NA                                                                            | [47]       |
| *Ikkr*Δ/Δ.K14.Cre  | Die within 3 weeks; neonatal epidermal hyperplasia and severe inflammation           | Tnfr1 KO rescues mutants and skin lesions                                      | NA                                                                            | [48]       |
| *Ikka*Δ/Δ.K5.CreER | Skin inflammation, hairless, and spontaneous skin tumors                             | Not tested for Tnfr1 KO; Egrf+/− and EGFR inhibitor rescue                     | Egfr+/− and EGFR inhibitor prevents skin tumorigenesis                        | [37]       |
| *Ikka*Δ/Δ.K15.CreRIP | Skin inflammation, hairless, and spontaneous skin tumors                           | Not tested for Tnfr1 KO                                                       | EGFR inhibitor prevents skin tumorigenesis                                     | [37]       |
| *Ikkr*Δ/Δ.K14.CreER | Skin inflammation in some mice at 3–6 months of age                                  | Anti-TNFRI antibody rescues skin lesions                                       | No skin tumors reported                                                      | [49]       |
| *Ikkr*Δ/Δ.K14.CreER | No severe skin phenotypes                                                          | Not tested for Tnfr1 KO                                                       | No skin tumors reported                                                      | [48]       |
| *p65*Δ/RelaΔ/Δ.K5.Cre | No severe skin phenotypes                                                          | Not tested for Tnfr1 KO                                                       | No skin tumors reported                                                      | [50]       |
| *lck*Δ/Δ.K5.Cre    | Skin inflammation                                                                   | Tnf KO/Ltβ KO rescues skin phenotypes; increased NF-κB                       | No skin tumors reported                                                      | [50]       |
| *Ikka*Δ/ΔΔ/Δ; mutations 177/181-Ser/Allan | Defects in mammary gland development through reducing RANKL/RANK, normal skin         | Not tested for Tnfr1 KO                                                       | Reduced breast and prostate cancer                                            | [34,51]   |
| *Ikka*Δ/ΔΔ/Δ; mutations 44-Lys/Allan | Defects in central tolerance, autoimmunity, and mammary glands                      | Unpublished data: Tnfr1 KO partially reduces skin phenotypes                   | Spontaneous skin, lung, and esophageal tumors correlated with decreased IKKα levels | [22,23]   |

On the other hand, IKKα overexpression inhibited chemical carcinogen–induced skin SCC metastasis or UVB-mediated skin carcinogenesis in transgenic Tg-Lori.IKKα or Tg-K5.IKKα mice, in which the IKKα cDNA is controlled by the loricrin promoter or the keratin 5 promoter [24,52]. Furthermore, the hyperproliferative epidermis lacking...
IKKα expressed increased IL-1, IL-6, and TNFα associated with increased macrophage infiltration. In contrast, overexpressed IKKα does not activate IKK kinase or NF-κB activity in the skin of Tg-K5.IKKα mice [53]; instead, it represses Ikka deletion–mediated cytokine expression and macrophage infiltration in the skin of Ikkaβf/f;K5.Cre;K5-IKKα mice. Overall, IKKα represses inducible NF-κB–related inflammation in skin.

**Neonatal skin manifestations versus tumorigenesis.** Intriguingly, all Ikkaαβf/f;K14.Cre, Ikkerαβf/f;K14.Cre, and Ikkaαβf/f;K5.Cre (and Ikkaβαf/f;K14.Cre) newborn pups specifically lacking either Ikbbα, Ikccγ, or Ikka in skin keratinocytes look normal [37,47,48]. However, these mutant mice gradually develop severe skin inflammation and epidermal hyperplasia after three to four days and die within two to three weeks after birth (Table 2). Again, Tnfrf1 deletion rescues the skin and death phenotypes of Ikkaβf/f;K14.Cre and Ikkerαβf/f;K14.Cre mice but it does not do so for Ikkaαβf/f;K5.Cre and Ikkaαβf/f;K14.Cre mice [37,47,48]. In addition, the epidermal layer is thicker in newborn mice than in adult mice, and the newborn skin has shorter hair follicles than adult mouse skin. The microbiome is closely associated with hair follicles and skin [37]. Thus, it is possible that alterations in IKKβ, IKKγ, or IKKα expression alter microbiota, which may contribute to epidermal hyperplasia and skin inflammation phenotypes in Ikkaβf/f;K14.Cre, Ikkerαβf/f;K14.Cre, and Ikkaαβf/f;K5.Cre neonatal mice. Furthermore, inducible ablation of either Ikbbα, Ikccγ, or Ikka in the skin of adult mice may have less of an effect on skin microbiota than in neonatal skin. Of note, Ikxaαβf/f;K5.Cre and Ikxaαβ−/− mice show severe skin inflammation, whereas p65(Rela)f/f;K5.Cre mice develop normally [28,50,54] (Table 2). Taken together, it remains largely unclear whether and how IKK and NF-κB are involved in maintaining microbiota-related skin homeostasis and tumorigenesis.

Although Tnfrf1 knockout does not rescue Ikkaαβf/f;K5.Cre;Tnfrf1−/− mice, the mutant skin highly express TNFα compared to WT [37]. Instead, EGFR reduction rescues a fraction of Ikkaαβf/f;K5.Cre;Egfrf/f mice characterized by hairlessness, suggesting that IKKα’s targets include EGFR during neonatal skin development. Inducible Ikkaαβf/f;K5.CreER and Ikkaαβf/f;K15.CreRpl mice develop spontaneous skin tumor development, and treatment with GW2974, an EGFR inhibitor, prevents the tumorigenesis (Table 2). Inducible Ikccγ deletion in adult mice did not cause skin diseases, and inducible Ikbbα deletion induced skin inflammation in some mutant mice [48,49]. There are no skin tumors reported in mice with inducible Ikbbα or Ikccγ deletion in the skin. These analyses indicate that IKKα loss and reduction elevate the expression of NF-κB targets, such as TNFα and IL-1, which are correlated with skin inflammation and tumorigenesis. Furthermore, Tnfrf1−/− and Tnfaαβ−/− mice are resistant to chemical carcinogen–induced skin carcinogenesis compared to WT mice [55,56]. Although these cytokines, such as TNFα, are not required for mouse embryonic and skin development, these induced inflammatory cytokines can stimulate inflammation-associated carcinogenesis. Taken together, these results suggest that the different events take place at different stages of embryonic skin, neonatal skin, and skin tumor development. Many questions remain to be addressed.

**Impaired central tolerance-mediated autoinflammation.** The cause of skin inflammation and spontaneous tumors developed in Tg-K5.mIkBα mice remains a mystery, although Tnfrf1 deletion rescues the skin phenotypes in Tg-K5.mIkBα mice [20,21]. Over the past several years, we have learned that RANK/RANKL, CD40/CD40L, LTβR/LTβ, IKKα, NIK, and RelB are required to develop medullar thymic epithelial cells (mTECs) [23,57–64]. The autoimmune regulator, which is expressed in mTEC, regulates the expression of tissue restrict antigens and other regulators that maintain the thymic microenvironment, which helps delete autoreactive T cells within the thymus and establish central tolerance [65]. Kinase-dead IKKα (IKKα-KA/KA), in which a lysine is replaced by an alanine at amino acid 44, an ATP binding site within the protein kinase domain, attenuates NF-κB (p65/p50) activity in mTEC and severely impairs mTEC and central tolerance development in Ikkaαβf/f;K5.Cre;K5-IKKα mice (Table 2) [23]. The IKKβ and IKKγ levels in Ikkaαβf/f;K5.Cre;K5-IKKα mice are decreased compared to WT. Different thymic stromal cells express distinct keratins, and mTEC expresses K5 [23]. Reintroduction of Tg-K5.IKKα partially elevates p65/p50 activity, rescues mTEC devel-
opment, and dampens autoimmune phenotypes in Ikka\textsuperscript{KA/KA}, Tg-K5.IKKα mice compared to Ikka\textsuperscript{KA/KA} mTEC and Ikka\textsuperscript{KA/KA} mice. Therefore, a defect in IKKα and NF-κB pathways results in negative T-cell selection, central tolerance defects, and autoimmune diseases. Ikka\textsuperscript{KA/KA} newborn mice look normal. After three months, the mutants start to show autoimmune phenotypes, and with increasing age, the phenotypes become worse.

To date, mice lacking Rank, Rankl, Cd40, Cd40l, Ltfβr, Ltfβ, or Nik develop autoimmunity, but none of these knockout mice develop spontaneous tumors [57–60]. Gradually decreased IKKα levels in epithelial cells are correlated with severe skin inflammation and tumorogenesis, as Ikka\textsuperscript{KA/KA} mice age [23,66]. We demonstrated that the autoreactive CD4 T cells initiate the skin autoinflammatory phenotypes with increased macrophage and neutrophil numbers, inflammasome activity (NLRP3), uric acid levels, and expression of CCL2, CXCR2, CXCL1, and IL-1β in Ikka\textsuperscript{KA/KA} skin compared to WT [66]. NLRP3 inhibition or CCL2/CXCR2 deletion rescued the skin phenotypes in the mutant mice. Although Tnfr1 deletion does not rescue the skin and death phenotypes in Ikka\textsuperscript{β/β},K5.Cre mice [37], its knockout improves Ikka\textsuperscript{KA/KA} skin phenotypes (unpublished data), suggesting that an overexpressed TNF/TNFRI pathway may be involved in the skin phenotypes of adult Ikka\textsuperscript{KA/KA} mice but is not a cause for Ikka ablation-initiated embryonic and neonatal skin phenotypes.

Moreover, an overexpressed K5.IKKα transgenic partially regulates mTEC and central tolerance development [23,67]. Most likely, the biological impact of the specific K5 promoter-driven transgenic gene is earlier than the function of the K5 promoter-driven Cre on the central tolerance establishment during embryonic thymus development because the specific Cre takes two steps and the transgenic gene only takes one step to execute its biological activities. Thus, Tg-K5.mIkBα mice may show autoinflammation-associated skin tumors because overexpressed mIkBα may downregulate NF-κB activity in mTEC [23], but IκBα\textsuperscript{β/β},K5.Cre mice may not develop the autoinflammatory phenotypes [50]. Furthermore, our unpublished finding showed that IKKα-KA/KA binds to IkBα more strongly than WT IKKα does. We then hypothesize that kinase-inactivated IKKα and unphosphorylated mIkBα enhance their interaction in the cytosol, which may ameliorate nuclear IKKα levels that regulate cell differentiation, proliferation, and tumorogenesis, and that overexpressed mIkBα may block IKKα anti-tumor activity. The K5 promoter is a very strong promoter to highly express the transgenic in mice [24]. Thus, overexpression of mIkBα may have additional events beyond NF-κB pathways. Moreover, the overexpressed mIkBα has been shown to promote the development of SCC derived from activated HRAS SCC cells [68]. In contrast, overexpressed p65 or p50 increase cell senescence, suggesting that increased NF-κB inhibits skin SCC development, while decreased NF-κB promotes skin SCC development by regulating cell senescence [68]. The same mutations in the IκBα gene, which encodes IkBα, may not appear in human cancers (TCGA database). In general, NF-κB transcription factors regulate the expression of a broad spectrum of cytokines and chemokines that modulate tumor cell growth and survival and the tumor microenvironment. Some of IKKα’s targets share NF-κB’s pathways during inflammation and tumor development. We need to further reveal how IKKα regulates the expression of the inflammatory cytokines.

2.1.2. Lung SCC, Esophageal SCC, and Nasopharyngeal Carcinoma

The basal cells in the internal surface of lung air tubes, esophagi, and nasopharynges, which express K5/K14 and p63, are squamous-like epithelial cells. Like keratinocytes, these cells can be induced to differentiate and proliferate as well as give rise to well-differentiated papillomas and undifferentiated malignant carcinomas. Ikka\textsuperscript{KA/KA} mice at six to 10 months of age on an FVB background develop spontaneous lung SCCs [22]. The IKKα levels in the lungs of Ikka\textsuperscript{KA/KA} newborn pups are similar to WT. From four to 16 weeks of age, the IKKα levels are gradually decreased, which is associated with lung SCC development [22]. Reintroduced transgenic IKKα prevents lung SCC development. Thus, IKKα reduction promotes lung carcinogenesis. The mouse Ikka\textsuperscript{KA/KA} lung SCCs express human lung SCC molecular traits, including reduced tumor suppressor p53 and Rb1, and overexpressed p63,
Trim29, ROS1, Rhov, c-Myc, and stem cell markers. In addition, depleting macrophages prevents lung SCC development in this setting. Thus, the significantly increased number of infiltrating macrophages is essential for lung SCC development in \(Ikka^{KA/KA}\) mice. We detected increased expression of TNF\(\alpha\), IL-1\(\beta\), IL-6, IL-13, CCL2, CXCL5, CXCL11, and CXCL8 in \(Ikka^{KA/KA}\) lungs compared to WT lungs. These chemokines promote macrophage induction, migration, and recruitment [22,69,70]. Of note, these lung SCC and WT lungs express comparable p65 levels, suggesting that IKK\(\alpha\) reduction does not downregulate NF-\(\kappa\)B expression, though it is associated with marked expression of multiple cytokines, chemokines, and macrophage infiltration during lung SCC development.

The esophagus is one organ of the gastrointestinal tract, and it frequently has contact with environmental infectious agents. The immune system prevents bacterial and fungal colonization and expansion. Of interest, most esophageal SCCs (ESCCs) are found in China and South Asia, where the weather is humid and damp. Such an environment can foster fungal growth and contaminate food. We found that these human ESCCs are associated with increased fungal infection [23]. Defects in immunity or epithelial cells allow bacterial and fungal colonization in the oral and esophageal organs, promoting disease pathogenesis. \(Ikka^{KA/KA}\) mice not only develop autoinflammation but show downregulated IL-17 expression in T cells in response to fungal stimulation [23]. IL-17 fights against fungal infection [71,72]. C57BL6 \(Ikka^{KA/KA}\) mice showed increased fungal colonization in the oral cavity and esophagi, and approximately 20% of five-month-old \(Ikka^{KA/KA}\) mice develop spontaneous ESCC. Oral fungal inoculations promote ESCC incidence, while anti-fungal drug treatment decreases ESCC development in \(Ikka^{KA/KA}\) mice [23]. Thus, increased fungal infection promotes ESCC development. These mouse ESCCs expressed reduced IKK\(\alpha\), p53, and p16 but increased EGFR activity and p63, which are the hallmarks for human ESCCs. They also express increased NF-\(\kappa\)B1 and many cytokines and chemokines, including CCL7, CCL8, and IL-23, with infiltrating macrophages that express increased PD-L1, TNF\(\alpha\), and IL-6 [23]. Anti-fungal drug treatment decreased in infiltrating macrophage numbers and carcinogenesis. Overall, infection-mediated inflammation promotes esophageal carcinogenesis.

Nasopharyngeal carcinoma (NPC), which frequently occurs in Southeast Asia, is a deadly disease, because more than 95% of patients with NPC have type III undifferentiated carcinomas at first diagnosis [40]. NPC arises from the pharyngeal mucosal space and is associated with Epstein-Barr virus infection in most cases. Downregulated CHUK/IKK\(\alpha\) expression is significantly correlated with aggressive and undifferentiated NPCs that express increased K13 and decreased vimentin [40]. IKK\(\alpha\) deletion in human NPC cells promotes tumorigenesis, but reintroduced IKK\(\alpha\) inhibits tumorigenesis derived from human NPC cells. EZH2 is identified as an inhibitor for downregulating IKK\(\alpha\) expression via increasing the methylation on the \(Ikk\alpha\) promoter. Also, decreased IKK\(\alpha\) expression is correlated with increased ERK activity and expression of VEGF and MMP9 in these human NPCs. Whether IKK\(\alpha\) reduction modulates the tumor microenvironment requires further investigation.

2.2. Adenocarcinoma

ADC is a type of cancer that originates from lung, pancreas, colon, prostate, or esophageal glands. The Cancer Genome Atlas (TCGA) database reveals activated KRAS mutations in approximately 35% of human lung ADCs, 90% of pancreatic ductal adenocarcinomas (PDACs), and 45% of colorectal ADCs (cBioPortal, Nature 2014, Nature 2016, and PanCancer Atlas). A high rate for activated KRAS mutations is a common feature for these different human ADCs.

2.2.1. Lung ADC

Lung ADC is derived from lung type II alveolar epithelial cells. CHUK nonsense mutations and homozygous/hemizygous deletions were found in human lung ADCs (cBioPortal, TCGA, Nature 2014) [38]. Patients with lung ADCs carrying double CHUK
hemizygous deletions and KRAS mutations have significantly decreased survival rates compared to patients with KRAS mutations alone. \textit{Ikka} deletion specific in the lungs, induced by intratracheally injected adenovirus-Cre, causes spontaneous lung ADC development and promotes \textit{Kras}\textsuperscript{G12D}-initiated lung ADC development in \textit{Kras}\textsuperscript{G12D,Ikka}\textsuperscript{ALU} (\textit{Ikka} deletion in the lungs) mice (Table 3). Although the levels of NF-κB components are comparable in \textit{Kras}\textsuperscript{G12D} lung ADC and \textit{Kras}\textsuperscript{G12D,Ikka}\textsuperscript{ALU} ADCs, IKKα reduction in the lung ADCs elevated the expression of inflammatory cytokines and chemokines, including NF-κB targets [38]. Reintroducing IKKα into ADC cells suppressed tumor incidence and burden derived from the ADC cells in the lungs and repressed the expression of multiple cytokines, which indicates that impaired IKKα expression in cancer cells regulates the tumor microenvironment.

| Mice                          | Tumorigenesis                  | NF-κB activity                                      | References |
|-------------------------------|--------------------------------|-----------------------------------------------------|------------|
| \textit{Ikka}\textsuperscript{f/f};Ad.Cre-intratracheal | Spontaneous lung ADC; promoted \textit{Kras}\textsuperscript{G12D}-mediated lung ADC | Similar NF-κB activity in these ADCs from different groups | [38]       |
| \textit{Ikka}\textsuperscript{f/f};Sftpc.Cre\textsuperscript{ER} | Promoted carcinogen-induced lung ADC development | p52 reduction inhibited ADC development derived from human ADC cells | [73]       |
| \textit{Ikka}\textsuperscript{f/f};Sftpc.Cre or Scgb1a1.Cre | Inhibited \textit{Kras}\textsuperscript{G12D,mediated lung ADC development} | Reduced NF-κB activity | [74]       |
| \textit{Ikka}\textsuperscript{f/f};Pdx-1.Cre | Promoted \textit{Kras}\textsuperscript{G12D,mediated pancreatic carcinoma} | Not tested | [39]       |
| IKKβ depletion | Inhibited lung epithelial proliferation and \textit{Kras}\textsuperscript{G12D}-mediated lung ADCs | Inhibited NF-κB activity | [75,76] |

In addition, specifically induced \textit{Ikka} ablation in lung type II epithelial cells by Sftpc-Cre\textsuperscript{ERT2} promotes a carcinogen-initiated lung cancer development, but IKKβ deletion inhibits lung ADC development in this setting (Table 3) [73]. We, like Chavdoula and colleagues, consistently demonstrated that IKKα deletion promotes the development of lung ADCs derived from a human ADC cell line, while reintroduced IKKα inhibits them [73]. Of note, p52 reduction inhibits lung tumorigenesis in the same setting [73]. These results suggest that NF-κB contributes to lung ADC development and that, during tumorigenesis, IKKα and NF-κB may function in two parallel pathways. Thus, the intriguing interplay between NF-κB and IKKα should be further investigated. Moreover, IKKβ deletion or NF-κB reduction inhibits lung epithelial cell proliferation and \textit{Kras}\textsuperscript{G12D}-mediated lung ADC development [75,76]. In contrast, another study reported an opposite finding in which deletion of \textit{Ikka} but not \textit{Ikkb} reduces \textit{Kras}\textsuperscript{G12D}-mediated lung ADC development through NF-κB activity [74], which is not supported by human TCGA data analyses [38].

2.2.2. Pancreatic ADC and Colorectal Carcinoma

Furthermore, patients with PADC carrying \textit{CHUK} mutations have decreased survival rates (cBioPortal, Pancreas). \textit{Ikka} deletion in pancreatic cells mediated by Pdx1-Cre induces pancreatitis associated with the increased expression of TNFα, IL-1β, IL-6, MCP-1, and RANTES, which are NF-κB’s targets [77]. Patients with pancreatitis have increased incidence of pancreatic cancer. In addition, \textit{Ikka} deletion significantly promotes \textit{Kras}\textsuperscript{G12D,initiated PDAC development in mice (Table 3)} [39]. Thus, IKKα reduction in pancreatic cells promotes inflammation associated with NF-κB targets.

Activated \textit{KRAS} mutations are found in 40–50% of human colorectal carcinomas (cBioPortal, TCGA, Colorectal Adenocarcinoma cohorts). Meanwhile, the gut microbiota regulates carcinogenesis. In mouse models, chemical irritants and carcinogens have been broadly used for studying inflammation-associated colitis and carcinoma development. In
this setting, Ikkα deletion in the intestinal epithelial cell (IEC) increases *Citrobacter rodentium* infection, and associated inflammation promotes DSS-mediated colitis [78]. Ikkα deletion in IEC cells recruits type III innate lymphocytes by elevating thymic stromal lymphopoietin to downregulate IL-22 in Ikkα^{IEC} mice. On the other hand, Ikkβ inactivation in IEC cells reduces colitis, which is the opposite of Ikkα ablation. This indicates IKKα and IKKβ have a distinct role in inflammation formation and colitis development [78]. Thus, IKKα prevents induced inflammation and is required for intestine-colon homeostasis in response to infectious and inflammatory stimuli. Interestingly, Nik deletion, as well as *Ltb*r deletion, increased inflammation in the colon following DSS treatment [79]. Therefore, the relationship of NIK, IKKα, and NF-κB in this setting needs further investigation.

2.3. Breast Cancer and Prostate Cancer

Breast and prostate cancers are related to hormone alterations. Interestingly, TCGA (cBioPortal, METABRIC, Nature 2012 & Nat Commun 2016) data analyses show that a proportion of these human cancers show increased or amplified cyclin D1, which is encoded by the CCND1 oncogenic gene. RANKL and RANK, the TNFR family members, regulate mammary gland development [80]. Consistently, kinase-inactive Ikkα knock-in (Ikkα^{AA}) mice, in which two serine residues were replaced by alanine residues at amino acid 177 and 181, show a defect in mammary gland development [34]. Ikkα^{AA} mammary epithelial lobuloalveolar cells reduced growth and NF-κB activity in response to RANKL but not TNFα treatment in a culture system [34]. Mammary tumorigenesis is inhibited in Ikkα^{AA};Tg-MMTV.cyclin D1 mice as well as in Tg-MMTV.mIκBα mice compared to Tg-MMTV.cyclin D1 mice [34]. Thus, NF-κB is important for breast tumor development through RANKL/RANK/Ikkα to the oncogene cyclin D1. Also, RANK/RANKL is involved in human breast cancer and has been used for therapeutic targets. The kinase-dead Ikkα knock-in (Ikkα^{KA/KA}) mice develop a more severe defect in the mammary gland compared to Ikkα^{AA} mice (unpublished data). In addition, the Ikkα^{KA/KA} female mice can have a single pregnancy with one or two babies and no milk production, and then these females because infertile (unpublished data). Whether an autoimmune condition contributes to this defect in reproductive organ development in Ikkα^{KA/KA} mice remains to be investigated [23]. Overall, Ikkα^{AA} mice and Ikkα^{KA/KA} mice share a common defect in mammary gland development, although these Ikkα^{KA/KA} mice develop additional spontaneous lung and skin SCC associated with IKKα reduction. Based on these results, the RANKL/RANK/IKKα pathway functions as a tumor promoter for the mammary gland cancer development.

TRAMP mice that overexpress SV40 in the prostate organ develop spontaneous prostate tumors [51]. The prostate tumorigenesis and metastasis were inhibited, which correlated with decreased expression of multiple cytokines, in Ikkα^{AA};TRAMP male mice through a NF-κB RANK/ANKL pathway to regulate the expression of Maspin that is a tumor suppressor, compared to TRAMP transgenic mice [51]. This finding suggests that NF-κB may stimulate prostate cancer development. Interestingly, a PHLPP/FKBP51/IKKα complex has been reported to upregulate NF-κB and AKT activity in castration-resistant prostate cancer development [81], although the specific role of IKKα in this complex needs to be determined. In the future, the effect of cell-specific Ikkα deletion on breast and prostate cancer development should be investigated.

3. Conclusions

Overall, NF-κB and its targets intensify inflammation and accelerate SCC and ADC tumorigenesis. On the other hand, defective immunity-mediated systemic autoinflammation, initiated by germline IKK/NF-κB inactivation in the lymphoid organ, which cooperates with oncogenes or tumor suppressors, can also contribute to tumorigenesis. Thus, NF-κB can regulate tumorigenesis at different stages. IKKα reduction and ablation result in cutaneous, lung, oral, esophageal, nasopharyngeal, and pancreatic carcinogenesis associated with increased inflammation. IKKα inactivation–induced inflammation shows a
similar pattern to that mediated by NF-κB activation. These findings will provide potential therapeutic targets for human cancer.

To date, most studies focus on IKKα, TNFR family members, and carcinogenesis. We still do not know about the crosstalk between IKKα-mediated pathways and Toll-like receptor pathways. Of note, the microbiota plays important roles in modulating inflammation and carcinogenesis. This may explain some contradictory results for IKK and NF-κB among different laboratories. In addition, we found that increased inflammation downregulates IKKα levels in tumors. Thus, the in vitro cultured cell lines may have higher IKKα levels than in vivo tumors. Furthermore, by western blotting, a non-specific band close beneath the IKKα band can mask a real IKKα protein band when IKKα levels are examined in mouse and human tissues, which may also contribute to the disagreements regarding IKKα expression among different laboratories.

**Author Contributions:** Conceptualization, X.L. and Y.H.; software, X.L.; writing—original draft preparation, X.L. and Y.H.; writing—review and editing, X.L. and Y.H.; funding acquisition, Y.H. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by National Cancer Institute (ZIA BC011212 and ZIA BC011212) to Y.H. This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** This research was funded by National Cancer Institute (ZIA BC011212 and ZIA BC011212) to Y.H.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Hayden, M.S.; West, A.P.; Ghosh, S. NF-κB and the immune response. *Ontogene* 2006, 25, 6758–6780. [CrossRef]
2. Xing, L.; Carlson, L.; Story, B.; Tai, Z.; Keng, P.; Siebenlist, U.; Boyce, B.F. Expression of either NF-κB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. *J. Bone Miner. Res.* 2003, 18, 260–269. [CrossRef]
3. Ghosh, S.; Karin, M. Missing pieces in the NF-κB puzzle. *Cell* 2002, 109 (Suppl. 1), S81–S96. [CrossRef]
4. Sun, S.C. The non-canonical NF-κB pathway in immunity and inflammation. *Nat. Rev. Immunol.* 2017, 17, 545–558. [CrossRef]
5. Senftleben, U.; Cao, Y.; Xiao, G.; Greten, F.R.; Krahn, G.; Bonizzi, G.; Chen, Y.; Hu, Y.; Fong, A.; Sun, S.C.; et al. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. *Science* 2001, 293, 1495–1499. [CrossRef] [PubMed]
6. Makris, C.; Godfrey, V.L.; Krahn-Senftleben, G.; Takahashi, T.; Roberts, J.L.; Schwarz, T.; Feng, L.; Johnson, R.S.; Karin, M. A cytokine-responsive IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. *Cell* 1997, 91, 243–252. [CrossRef]
7. Connelly, M.A.; Marcu, K.B. CHUK, a new member of the helix-loop-helix and leucine zipper families of interacting proteins, contains a serine-threonine kinase catalytic domain. *Cell. Mol. Biol. Res.* 1995, 41, 537–549. [PubMed]
8. DiDonato, J.A.; Hayakawa, M.; Rothwarf, D.M.; Zandi, E.; Karin, M. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. *Nature* 1997, 388, 548–554. [CrossRef]
9. Mercurio, F.; Zhu, H.; Murray, B.W.; Shevchenko, A.; Bennett, B.L.; Li, J.; Young, D.B.; Barbosa, M.; Mann, M.; Manning, A.; et al. IKK-1 and IKK-2: Cytokine-activated IκB kinases essential for NF-κB activation. *Science* 1997, 278, 860–866. [CrossRef]
10. Hu, Y.; Baud, V.; Delhase, M.; Zhang, P.; Deerinck, T.; Ellisman, M.; Johnson, R.; Karin, M. Abnormal morphogenesis but intact IKK activation in mice lacking the IκKα subunit of IκB kinase. *Science* 1999, 284, 316–320. [CrossRef] [PubMed]
11. Doi, T.S.; Marino, M.W.; Takahashi, T.; Yoshida, T.; Sakakura, T.; Old, L.J.; Obata, Y. Absence of tumor necrosis factor factor rescues RelA-deficient mice from embryonic lethality. *Proc. Natl. Acad. Sci. USA* 1999, 96, 2994–2999. [CrossRef] [PubMed]
12. Makris, C.; Godfrey, V.L.; Krahn-Senftleben, G.; Takahashi, T.; Roberts, J.L.; Schwarz, T.; Feng, L.; Johnson, R.S.; Karin, M. Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. *J. Bone Miner. Res.* 2000, 15, 969–979. [CrossRef]
13. Schmidt-Supprian, M.; Bloch, W.; Courtot, G.; Addicks, K.; Israel, A.; Rajewsky, K.; Pasparakis, M. NEMO/IKK gamma-deficient mice model incontinentia pigmenti. *Mol. Cell* 2000, 5, 981–992. [CrossRef]
14. Li, Q.; Van Antwerp, D.; Mercurio, F.; Lee, K.F.; Verma, I.M. Severe liver degeneration in mice lacking the IκB kinase 2 gene. *Science* 1999, 284, 321–325. [CrossRef] [PubMed]
16. Li, Z.W.; Chu, W.; Hu, Y.; Delhase, M.; Deerinck, T.; Ellisman, M.; Johnson, R.; Karin, M. The IKKb subunit of IκB kinase (IKK) is essential for nuclear factor-κB activation and prevention of apoptosis. J. Exp. Med. 1999, 189, 1839–1845. [CrossRef] [PubMed]

17. Beg, A.A.; Sha, W.C.; Bronson, R.T.; Ghosh, S.; Baltimore, D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 1995, 376, 167–170. [CrossRef]

18. Li, Q.; Lu, Q.; Hwang, J.Y.; Buscher, D.; Lee, K.F.; Izpisua-Belmonte, J.C.; Verma, I.M. IKK1-deficient mice exhibit abnormal development of skin and skeletal muscle. Genes Dev. 1999, 13, 1322–1328. [CrossRef]

19. Park, E.; Zhu, F.; Liu, B.; Xia, X.; Shen, J.; Bustos, T.; Fischer, S.M.; Hu, Y. Reduction in IκB kinase α expression promotes the development of skin papillomas and carcinomas. Cancer Res. 2007, 67, 9158–9168. [CrossRef]

20. Van Hogerlinden, M.; Rozell, B.L.; Ahrlund-Richter, L.; Toftgard, R. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-κB signaling. Cancer Res. 1999, 59, 3299–3303.

21. Lind, M.H.; Rozell, B.; Wallin, R.P.; van Hogerlinden, M.; Ljunggren, H.G.; Toftgard, R.; Sur, I. Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF-κB inhibition. Proc. Natl. Acad. Sci. USA 2004, 101, 4972–4977. [CrossRef] [PubMed]

22. Xiao, Z.; Jiang, Q.; Willette-Brown, J.; Xi, S.; Zhu, F.; Burkett, S.; Back, T.; Song, N.Y.; Datla, M.; Sun, Z.; et al. The Pivotal Role of IKKα in the Development of Spontaneous Lung Squamous Cell Carcinomas. Cancer Cell 2013, 23, 527–540. [CrossRef] [PubMed]

23. Zhu, F.; Willette-Brown, J.; Song, N.Y.; Komada, D.; Song, Y.; Xue, L.; Gray, Z.; Zhao, Z.; Davis, S.R.; Sun, Z.; et al. Autoreactive T Cells and Chronic Fungal Infection Drive Esophageal Carcinogenesis. Cell Host Microbe 2017, 21, 478–493. [CrossRef] [PubMed]

24. Xia, X.; Park, E.; Liu, B.; Willette-Brown, J.; Gong, W.; Wang, J.; Mitchell, D.; Fischer, S.M.; Hu, Y. Reduction of IKKα expression promotes chronic ultraviolet B exposure-induced skin carcinogenesis and carcinogenesis. Am. J. Pathol. 2010, 176, 2500–2508. [CrossRef] [PubMed]

25. Page, A.; Navarro, M.; Garin, M.; Perez, P.; Casanova, M.L.; Moreno, R.; Jorcano, J.L.; Cascallana, J.L.; Bravo, A.; Ramirez, A. IKKβ leads to an inflammatory skin disease resembling interface dermatitis. J. Investig. Dermatol. 2010, 130, 1598–1610. [CrossRef] [PubMed]

26. Page, A.; Cascallana, J.L.; Casanova, M.L.; Navarro, M.; Alameda, J.P.; Perez, P.; Bravo, A.; Ramirez, A. IKKβ overexpression leads to pathologic lesions in stratified epithelia and exocrine glands and to tumoral transformation of oral epithelia. Mol. Cancer Res. 2011, 9, 1329–1338. [CrossRef] [PubMed]

27. Tetreault, M.P.; Weinblatt, D.; Ciolino, J.D.; Klein-Szanto, A.J.; Sackey, B.K.; Twyman-Saint Victor, C.; Karakashova, T.; Teal, V.; Katz, J.P. Esophageal Expression of Active IκB Kinase-β in Mice Up-Regulates Tumor Necrosis Factor and Granulocyte-Macrophage Colony-Stimulating Factor, Promoting Inflammation and Angiogenesis. Gastroenterology 2016, 150, 1609–1619.e11. [CrossRef]

28. Klement, J.F.; Rice, N.R.; Car, B.D.; Abbondanzo, S.J.; Powers, G.D.; Bhatt, P.H.; Chen, C.H.; Rosen, C.A.; Stewart, C.L. IκBα deficiency results in a sustained NF-κB response and severe widespread dermatitis in mice. Mol. Cell. Biol. 1996, 16, 2341–2349. [CrossRef]

29. Lahtela, J.; Nousiainen, H.O.; Stefanovic, V.; Tallila, J.; Viskari, H.; Karikoski, R.; Gentile, M.; Saloranta, C.; Varilo, T.; Salonen, R.; et al. Mutant CHUK and severe fetal encasement malformation. N. Engl. J. Med. 2010, 363, 1631–1637. [CrossRef]

30. Pannicke, U.; Baumann, B.; Fuchs, S.; Henneke, P.; Rensing-Ehl, A.; Rizzi, M.; Janda, A.; Hese, K.; Schlesier, M.; Holzmann, K.; et al. Deficiency of innate and acquired immunity caused by an IKKβ mutation. N. Engl. J. Med. 2013, 369, 2504–2514. [CrossRef]

31. Nielsen, C.; Jakobsen, M.A.; Larsen, M.J.; Muller, A.C.; Hansen, S.; Lillevang, S.T.; Fisker, N.; Barington, T. Immunodeficiency associated with a nonsense mutation of IKKβ. J. Clin. Immunol. 2014, 34, 916–921. [CrossRef]

32. Mousalam, T.; Yang, J.; Urban, T.J.; Wang, H.; Adeli, M.; Parrott, R.E.; Roberts, J.L.; Goldstein, D.B.; Buckley, R.H.; Zhong, X.P. A nonsense mutation in IKKβ causes combined immunodeficiency. Blood 2014, 124, 2046–2050. [CrossRef]

33. Burns, S.O.; Plaggan, V.; Gutierrez, B.M.; Ali Zahrani, D.; Curtis, J.; Gaspar, M.; Hassan, A.; Jones, A.M.; Malone, M.; Ramlpling, D.; et al. Immunodeficiency and disseminated mycobacterial infection associated with homozygous nonsense mutation of IKKβ. J. Allergy Clin. Immunol. 2014, 134, 215–218. [CrossRef]

34. Cao, Y.; Bonizzi, G.; Seagroves, T.N.; Greten, F.R.; Johnson, R.; Schmidt, E.V.; Karin, M. IKKα provides an essential link between RANK signaling and cyclooxygenase 2 expression during mammary gland development. Cell 2001, 107, 763–775. [CrossRef]

35. Maeda, G.; Chiba, T.; Kawashiri, S.; Satoh, T.; Imai, K. Epigenetic inactivation of IκB Kinase-α in oral carcinomas and tumor progression. Clin. Cancer Res. 2007, 13, 5041–5047. [CrossRef] [PubMed]

36. Descargues, P.; Sih, A.K.; Sano, Y.; Horochynskyi, O.; Han, G.; Owens, P.; Wang, X.J.; Karin, M. IKKα is a critical coregulator of a Smad4-independent TGF-β-Smad2/3 signaling pathway that controls keratinocyte differentiation. Proc. Natl. Acad. Sci. USA 2008, 105, 2487–2492. [CrossRef] [PubMed]

37. Liu, B.; Xia, X.; Zhu, F.; Park, E.; Carabajal, S.; Kiguchi, K.; DiGiovanni, J.; Fischer, S.M.; Hu, Y. IKKα is required to maintain skin homeostasis and prevent skin cancer. Cancer Cell 2008, 14, 212–225. [CrossRef] [PubMed]

38. Song, N.Y.; Zhu, F.; Wang, Z.; Willette-Brown, J.; Xi, S.; Sun, Z.; Su, L.; Wu, X.; Ma, B.; Nussinov, R.; et al. IKKα inactivation promotes Kras-initiated lung adenocarcinoma development through disrupting major redox regulatory pathways. Proc. Natl. Acad. Sci. USA 2018, 115, E812–E821. [CrossRef] [PubMed]

39. Todoric, J.; Antonucci, L.; Di Caro, G.; Li, N.; Wu, X.; Lytle, N.K.; Dhar, D.; Banerjee, S.; Fagman, J.B.; Browne, C.D.; et al. Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas. Cancer Cell 2017, 32, 824–839.e8. [CrossRef]
40. Yan, M.; Zhang, Y.; He, B.; Xiang, J.; Wang, Z.F.; Zheng, F.M.; Xu, J.; Chen, M.Y.; Zhu, Y.L.; Wen, H.J.; et al. IKKα restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation. Nat. Commun. 2014, 5, 3661. [CrossRef] [PubMed]
41. Hu, Y.; Baud, V.; Oga, T.; Kim, K.I.; Yoshida, K.; Karin, M. IKKα controls formation of the epidermis independently of NF-κB. Nature 2001, 410, 710–714. [CrossRef]
42. Lee, J.C.; Kundu, J.K.; Hwang, D.M.; Na, H.K.; Surh, Y.J. Humulone inhibits phorbol ester-induced COX-2 expression in mouse skin by blocking activation of NF-κB and AP-1: IkB kinase and c-Jun-N-terminal kinase as respective potential upstream targets. Carcinogenesis 2007, 28, 1499–1504. [CrossRef] [PubMed]
43. Martin, B.N.; Wang, C.; Willette-Brown, J.; Herjan, T.; Gulen, M.F.; Zhou, H.; Bulek, K.; Franchi, L.; Sato, T.; Alnemri, E.S.; et al. IKKα negatively regulates ASC-dependent inflammasome activation. Nat. Commun. 2014, 5, 4977. [CrossRef] [PubMed]
44. Lawrence, T.; Bebien, M.; Liu, G.Y.; Nizet, V.; Karin, M. IKK family kinase establishes self-tolerance in a thymic stroma-dependent manner. J. Immunol. 2008, 180, 429–437. [CrossRef] [PubMed]
45. Rehbolz, B.; Haase, I.; Eckett, B.; Paxian, S.; Flag, M.J.; Ghoreschi, K.; Nedospasov, S.A.; Mollhammer, R.; Debey-Pascher, S.; Schultz, J.I.; et al. Crossstalk between keratinocytes and adaptive immune cells in an IkBα protein-mediated inflammatory disease of the skin. Immunity 2007, 27, 296–307. [CrossRef] [PubMed]
46. Luo, J.L.; Tan, W.; Ricono, J.M.; Korchnytskyi, O.; Zhang, M.; Gonias, S.L.; Cheresh, D.A.; Karin, M. Nuclear cytokine-activated IKK controls prostate cancer metastasis by repressing Maspin. Nature 2007, 446, 690–694. [CrossRef] [PubMed]
47. Liu, B.; Park, E.; Zhu, F.; Bustos, T.; Liu, J.; Shen, J.; Fischer, S.M.; Hu, Y. A critical role for IkB kinase α in the development of human and mouse squamous cell carcinomas. Proc. Natl. Acad. Sci. USA 2006, 103, 17202–17207. [CrossRef] [PubMed]
48. Liu, B.; Willette-Brown, J.; Liu, S.; Chen, X.; Fischer, S.M.; Hu, Y. IKKα represses a network of inflammation and proliferation pathways and elevates c-Myc antagonists and differentiation in a dose-dependent manner in the skin. Cell Death Differ. 2011, 18, 1854–1864. [CrossRef] [PubMed]
49. Nenci, A.; Huth, M.; Funeh, A.; Schmidt-Supprian, M.; Bloch, W.; Metzger, D.; Chambon, P.; Rajewsky, K.; Haase, I.; et al. Skin lesion development in a mouse model of incontinentia pigmenti is triggered by NEMO deficiency in epidermal keratinocytes and requires TNF signaling. Hum. Mol. Genet. 2006, 15, 531–542. [CrossRef]
50. Stratis, A.; Pasparakis, M.; Rupe, R.A.; Markur, D.; Hartmann, K.; Scharffetter-Kochanek, K.; Peters, T.; van Rooijen, N.; Krieg, T.; Haase, I. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J. Clin. Investig. 2006, 116, 2094–2104. [CrossRef] [PubMed]
51. Krumm, H.; et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 2002, 417, 861–866. [CrossRef] [PubMed]
52. Liu, B.; Willette-Brown, J.; Liu, S.; Chen, X.; Fischer, S.M.; Hu, Y. IKKα negatively regulates ASC-dependent inflammasome activation. J. Immunol. 2013, 190, 5834–5842. [CrossRef] [PubMed]
53. Moore, R.J.; Owens, D.M.; Stamp, G.; Arnott, C.; Burke, F.; East, N.; Holdsworth, H.; Turner, L.; Rollins, B.; Pasparakis, M.; et al. Mice deficient in tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24-dependent psoriasis-like skin disease. J. Immunol. 2011, 187, 4516–4518. [PubMed]
54. Suganuma, M.; Okabe, S.; Marino, M.W.; Sakai, A.; Sueoka, E.; Fujiki, H. Essential role of tumor necrosis factor alpha (TNF-alpha) controls formation of the epidermis independently of NF-κB. Cancer Res. 1999, 59, 4516–4518. [PubMed]
55. Akiyama, T.; Shimo, Y.; Yanai, H.; Qin, J.; Ohshima, D.; Maruyama, Y.; Asaumi, Y.; Kitazawa, J.; Takayanagi, H.; et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 2002, 417, 861–866. [CrossRef] [PubMed]
56. Weih, F.; Carrasco, D.; Durham, S.K.; Barton, D.S.; Rizzo, C.A.; Ryseck, R.P.; Lira, S.A.; Bravo, R. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κB/Rel family. Cell 1995, 80, 331–340. [CrossRef]
57. Weih, F.; Carrasco, D.; Durham, S.K.; Barton, D.S.; Rizzo, C.A.; Ryseck, R.P.; Lira, S.A.; Bravo, R. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κB/Rel family. Cell 1995, 80, 331–340. [CrossRef] [PubMed]
58. Liu, B.; Willette-Brown, J.; Liu, S.; Chen, X.; Fischer, S.M.; Hu, Y. IKKα represses a network of inflammation and proliferation pathways and elevates c-Myc antagonists and differentiation in a dose-dependent manner in the skin. Cell Death Differ. 2011, 18, 1854–1864. [CrossRef] [PubMed]
59. Krumm, H.; et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 2002, 417, 861–866. [CrossRef] [PubMed]
60. Krumm, H.; et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 2002, 417, 861–866. [CrossRef] [PubMed]
64. Lomada, D.; Liu, B.; Coghlan, L.; Hu, Y.; Richie, E.R. Thymus Medulla Formation and Central Tolerance Are Restored in IKKα−/− Mice That Express an IKKα Transgene in Keratin 5+ Thymic Epithelial Cells. *J. Immunol.* 2007, 178, 829–837. [CrossRef] [PubMed]

65. Mathis, D.; Benoist, C. Aire. *Annu. Rev. Immunol.* 2009, 27, 287–312. [CrossRef] [PubMed]

66. Zhu, F.; Willette-Brown, J.; Zhang, J.; Ferre, E.M.N.; Sun, Z.; Wu, X.; Lionakis, M.S.; Hu, Y. NLRP3 Inhibition Ameliorates Severe Cutaneous Autoimmune Manifestations in a Mouse Model of Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy-Like Disease. *J. Investig. Dermatol.* 2020. [CrossRef]

67. Zhu, F.; Hu, Y. Integrity of IKK/NF-κB Shields Thymic Stroma That Suppresses Susceptibility to Autoimmunity, Fungal Infection, and Carcinogenesis. *Bioessays* 2018, 40, e1700131. [CrossRef] [PubMed]

68. Dajee, M.; Lazarov, M.; Zhang, J.Y.; Cai, T.; Green, C.L.; Russell, A.; Marinkovich, M.P.; Tao, S.; Lin, Q.; Kubo, Y.; et al. NF-κB blockade and oncogenic Ras trigger invasive human epithelial neoplasia. *Nature* 2003, 421, 639–643. [CrossRef] [PubMed]

69. Wang, X.; Gray, Z.; Willette-Brown, J.; Zhu, F.; Shi, G.; Jiang, Q.; Song, N.Y.; Dong, L.; Hu, Y. Macrophage inducible nitric oxide synthase circulates inflammation and promotes lung carcinogenesis. *Cell Death Discov.* 2018, 4, 46. [CrossRef] [PubMed]

70. Gray, Z.; Shi, G.; Wang, X.; Hu, Y. Macrophage inducible nitric oxide synthase promotes the initiation of lung squamous cell carcinoma by maintaining circulated inflammation. *Cell Death Dis.* 2018, 9, 642. [CrossRef] [PubMed]

71. Puel, A.; Cypowyj, S.; Bustamante, J.; Wright, J.F.; Liu, L.; Lim, H.K.; Migaud, M.; Israel, L.; Chrabieh, M.; Audry, M.; et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. *Science* 2011, 332, 36–68. [CrossRef] [PubMed]

72. Dominguez-Villar, M.; Hafler, D.A. Immunology. An innate role for IL-17. *Science* 2011, 332, 47–48. [CrossRef] [PubMed]

73. Chavdoula, E.; Habiel, D.M.; Roupakia, E.; Markopoulos, G.S.; Vasilaki, E.; Kokkalis, A.; Polyzos, A.P.; Boleti, H.; Thanos, D.; Klinakis, A.; et al. CHUK/IKK-α loss in lung epithelial cells enhances NSCLC growth associated with HIF up-regulation. *Life Sci. Alliance* 2019, 2, e201900460. [CrossRef] [PubMed]

74. Vreka, M.; Lilis, I.; Papageorgopoulou, M.; Giotopoulou, G.A.; Lianou, M.; Giopanou, I.; Kanellakis, N.I.; Spella, M.; Agalioti, T.; Armenis, V.; et al. IκB Kinase α Is Required for Development and Progression of KRAS-Mutant Lung Adenocarcinoma. *Cancer Res.* 2018, 78, 2939–2951. [CrossRef] [PubMed]

75. Xia, Y.; Yeddula, N.; Leblanc, M.; Ke, E.; Zhang, Y.; Oldfield, E.; Shaw, R.J.; Verma, I.M. Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. *Nat. Cell Biol.* 2012, 14, 257–265. [CrossRef] [PubMed]

76. Meylan, E.; Dooley, A.L.; Feldser, D.M.; Shen, L.; Turk, E.; Ouyang, C.; Jacks, T. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. *Nature* 2009, 462, 104–107. [CrossRef] [PubMed]

77. Li, N.; Wu, X.; Holzer, R.G.; Lee, J.H.; Todoric, J.; Park, E.J.; Ogata, H.; Gukovskaya, A.S.; Gukovsky, I.; Pizzio, D.P.; et al. Loss of acinar cell IκBα triggers spontaneous pancreatitis in mice. *J. Clin. Investig.* 2013, 123, 2231–2243. [CrossRef]

78. Giacomini, P.R.; Moy, R.H.; Noti, M.; Osborne, L.C.; Siracusa, M.C.; Alenghat, T.; Liu, B.; McCorkell, K.A.; Troy, A.E.; Rak, G.D.; et al. Epithelial-intrinsic IκKα expression regulates group 3 innate lymphoid cell responses and antibacterial immunity. *J. Exp. Med.* 2015, 212, 1513–1528. [CrossRef]

79. Ramakrishnan, S.K.; Zhang, H.; Ma, X.; Jung, I.; Schwartz, A.J.; Triner, D.; Devenport, S.N.; Das, N.K.; Xue, X.; Zeng, M.Y.; et al. Intestinal non-canonical NFκB signaling shapes the local and systemic immune response. *Nat. Commun.* 2019, 10, 660. [CrossRef]

80. Kiesel, L.; Kohl, A. Role of the RANK/RANKL pathway in breast cancer. *Maturitas* 2016, 86, 10–16. [CrossRef]

81. Wang, Z.; Yu, J.; Sun, L.; Tian, J.; Zhu, S.; Zhang, B.; Dong, Q.; Jiang, N.; Flores-Morales, A.; Chang, C.; et al. LncRNA PCAT1 activates AKT and NF-κB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKα complex. *Nucleic Acids Res.* 2019, 47, 4211–4225. [CrossRef] [PubMed]